Special Reports in Personalized Cancer Care Articles

Assays Break New Ground in Oncology
Two novel imaging agents and 6 clinical assays for use in cancer care gained the FDA's approval in 2016, marking advances in the diagnostic field.

In recent years, advancements in the treatment of patients with metastatic melanoma have proceeded in 2 areas: targeted therapies and immunotherapies.

Two of the most noteworthy developments in the oncology field during 2016 were the continued expansion of checkpoint blockade immunotherapy agents into more cancer types and the federal government’s plans for funding and remaking the research paradigm.
Although T cells have commanded most of the attention in the burgeoning immuno-oncology field, there is a growing appreciation that other immune cells have important roles in tumor surveillance and would represent attractive therapeutic targets.

Negative reports evaluating molecularly selected agents should not derail the process of developing future therapies by employing a precision medicine approach.

In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.
MSKCC Collaborates With Hackensack Meridian Health in Precision Medicine
To great fanfare, Hackensack Meridian Health of New Jersey and Memorial Sloan Kettering Cancer Center announced a co-branding partnership that they say would lead to highly fruitful collaborative research and make hundreds of clinical trial opportunities available to their patients.
President Obama Signs 21st Century Cures Act
President Barack Obama signed the 21st Century Cures Act into law today, earmarking $6.3 billion over 10 years for advancements in precision medicine development, brain research, heroin and prescription drug abuse prevention, and mental health.
Passed by House, 21st Century Cures Act Could Spur Advances, Weaken FDA
Viewed by some as a boon for precision medicine, an Alzheimer’s cure, brain research, and opioid abuse prevention, but also seen as weakening the FDA’s regulatory power, the $6.3 billion 21st Century Cures Act passed overwhelmingly in the House Wednesday by a vote of 392-26.
Investigating EGFR Resistance Leads to New Therapies, Advances in NSCLC
While resistance to EGFR-targeted therapies in non–small cell lung cancer presents a major challenge, there is a silver lining.
Publication Bottom Border
Border Publication